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Background: The DSM5-defined mixed features in depression do not include psychomotor 
agitation, irritability or distractibility because they are considered overlapping symptoms. 
A growing number of modern psychiatrists have expressed dissatisfaction with this and 
proposed alternative sets of mixed symptoms that are much more common and clinically 
relevant. Among such alternative criteria were those proposed by Koukopoulos. He utilized 
the research diagnostic criteria of agitated depression (RDC-A) as a mixed depression 
subtype, and validated another form of mixed depression, the Koukopoulos criteria for 
mixed depression (K-DMX).
Purpose: This study provides psychometric validation for the first self-rated scale designed 
to measure the most common mixed symptoms in depression as proposed by Koukopoulos.
Patients and Methods: We conducted a multicenter cross-sectional study of 170 patients 
with unipolar depression. They completed the Shahin Mixed Depression Scale (SMDS) and 
underwent expert interviews as a gold standard reference. SMDS’ psychometric properties 
were assessed, including Cronbach’s alpha, factor analysis, sensitivity, specificity, predictive 
value and accuracy.
Results: We found significant association and agreement between mixity according to 
SMDS and the gold standard (K-DMX and RDC-A according to expert interview) with 
good internal consistency (Cronbach’s alpha=0.87), high sensitivity (=91.4%), specificity 
(=98.0%), positive predictive value (=96.9%), negative predictive value (= 94.2%) and 
accuracy (=95.2%). Factor analysis identified one factor for psychomotor agitation and 
another for mixity without psychomotor agitation.
Conclusion: SMDS was a reliable and valid instrument for assessing the frequently 
encountered and clinically relevant mixed features in depression.
Keywords: mixed depression, mixed depression scale, major depressive disorder, 
psychomotor agitation, agitated depression, unipolar depression
Introduction
Irritability, psychomotor agitation and distractibility were considered overlapping 
symptoms and excluded from the DSM-5 definition of mixed depression (DMX).1 
Such a definition is poorly adjusted to the reality. Moreover, there is no mention in 
the earlier scientific literature of the DSM5-defined mixed symptoms (excluding 
pressured speech and flight of ideas).2
Including the overlapping symptoms, and psychomotor agitation is one of them, 
recent studies have reported a high prevalence of mixed depression both in samples 
of patients with bipolar disorder (BD) and major depressive disorder (MDD); for 
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instance, Koukopoulos et al3 reported a prevalence of 27% 
with both of their definitions of mixed depression (i.e. 
either motor or psychic agitated depression) among 361 
patients with bipolar and unipolar depression. In the same 
line, Maj et al4 found 19.5% agitated depression defined 
by the research diagnostic criteria5 (RDC) in 313 patients 
with BD. Benazzi,6 defining a mixed depressive state as 
a major depressive episode plus three or more hypomanic 
symptoms, including psychomotor agitation, irritability 
and distractibility, reported a prevalence of 43.9% among 
144 patients with unipolar depression (UP) and 218 BD 
type II patients. In the study of Takeshima and Oka,7 
psychomotor agitation is the most frequently observed 
hypo/manic symptom in both patients with BD (59.8%) 
and those with MDD (48.8%).
Moreover, a growing number of contemporary psychia-
trists have expressed dissatisfaction with the DSM-5 in 
considering psychomotor agitation as just a part of 
a subcriterion of major depression, proposing agitated 
depression as a mixed form of mood disorders.3,8–15
So, alternative diagnostic criteria of mixed depression 
have been proposed. They focused on the most common 
mixed symptoms, including psychomotor agitation, dis-
tractibility, irritability, racing/crowded thoughts, anger, 
increased talkativeness, indecisiveness, anxiety, emotional 
lability/tearfulness, inner tension, rumination, initial or 
middle insomnia, impulsivity and risky behaviors.16
One alternative set of mixed symptoms was proposed 
by Koukopoulos.2 He recommended giving the name agi-
tated depression to mixed depression with psychomotor 
agitation as defined by the research diagnostic criteria 
(RDC-A): the presence of at least two of the following 
manifestations of psychomotor agitation (not mere subjec-
tive anxiety) for several days during the current episode: 
pacing; hand wringing; unable to sit still; pulling or rub-
bing on hair, skin, clothing, or other objects; outburst of 
complaining or shouting; and over-talkativeness.5
He also proposed the name mixed depression 
(K-DMX) for mixed depression without psychomotor agi-
tation when at least three of the following symptoms are 
present along with MDD: inner tension/agitation, racing or 
crowded thoughts, irritability or unprovoked feeling of 
rage, absence of signs of retardation, talkativeness, dra-
matic description of suffering or frequent spells of weep-
ing, mood lability and marked emotional reactivity, and 
early insomnia. In his explanation, he believed that the 
origin of psychic pain, agitation and other mixed symp-
toms in depression is an underlying excitatory process.8
The specific diagnostic criteria for mixed depression 
without psychomotor agitation (K-DMX) have already 
been validated by a prior work by Sani et al.17
Although mixed depression with psychomotor agita-
tion, i.e. agitated depression (RDC-A) has yet to be vali-
dated as a mixed depression subtype, it seems to have 
diagnostic utility.18 Such a diagnostic utility could be 
related to its impact on treatment.19,20
Agitated depression (RDC-A) responds well to low- 
dose neuroleptics, lithium, anticonvulsants and electrocon-
vulsive therapy, whereas it shows marked deterioration in 
the patient’s condition in response to antidepressants,21–23 
in the form of increased agitation, insomnia, greater suf-
fering and the emergence of psychotic symptoms and 
suicidal ideas and impulses.
Based on the validity of K-DMX17 and the clinical utility 
of RDC-A as a mixed depression subtype,18–20 the aim of 
this study is to evaluate the psychometric properties of the 
Shahin Mixed Depression Scale (SMDS) in measuring the 
non-DSM, Koukopoulos-defined mixed features in depres-
sion in a sample of patients with unipolar depression.
Materials and Methods
Study Settings
The study was conducted at the outpatient psychiatric 
clinic of Mansoura University Hospital, at the Shahin 
private mood clinic in Cairo, and the outpatient clinic of 
a private mental hospital in Alexandria.
The sample size was calculated through Epi-Info 
(Epidemiological information package) software version 
6.1, according to the following collected data, taking into 
account that the frequency of the proposed non-DSM mixed 
depression is 33%–47% as reported by some studies,24,25 
with a confidence level 95% and a degree of precision 80%. 
The sample was 170, taken by systematic randomization.
Participants
A total of 170 consecutive patients (off drugs for at least 2 
weeks) with unipolar depressive disorder (UP) were ran-
domly enrolled in the study from July 1, 2019 to 
September 30, 2019. Their proportional allocation was as 
follows: 74 from Mansoura clinic, 68 from Shahin mood 
clinic and 28 from Alexandria clinic.
Inclusion Criteria
Patients with unipolar depression (UP), aged 19–65 years 
and diagnosed by clinical interview following DSM-5 
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criteria were included in the study. Montgomery–Asberg 
Depression Rating Scale (MADRS)26 was used to assess 
depressive symptoms. A score of 20 or greater had to be 
met for a clinical depressive episode. Hypomania 
Interview Guide-Current assessment Version (HIGH-C)27 
was used to test for significant concurrent hypo/manic 
symptoms. A score less than 8 was required for patients 
with UP to be included in the study, following Benazzi’s 
dimensional definition of mixed depression.28
Exclusion Criteria
To avoid confounding evaluation of the clinical picture, 
substance-related disorders, borderline personality disor-
der, psychotic symptoms, adult ADHD, dementia, mental 
retardation and intra-depressive hypo/manic symptoms 
mounting to DSM5-defined mixed depression diagnosis 
were excluded from the study (diagnosed by clinical inter-
view following DSM-5 criteria). Illiterate patients and 
patients with unstable or severe general medical conditions 
were also excluded.
Ethical Considerations
Official permission was obtained from Institutional 
Review Board (IRB) of Mansoura University. A verbal 
consent was obtained from the study group. It was 
informed verbal consent. The verbal consent process was 
approved by the IRB of Mansoura University. Our study 
complied with the Declaration of Helsinki.
Shahin Mixed Depression Scale (SMDS)
The SMDS is a self-rated screening test comprising two 
parts. The first part (items 1–6) represents psychomotor 
agitation as defined by the research diagnostic criteria5 
with a cutoff score greater than or equal to 2. The other 
subscale (items 6–13) matched Koukopoulos mixed fea-
tures K-DMX as validated by Koukopoulos and 
collaborators17 with a cutoff score greater than or equal 
to 3. Of note, item no. 6 i.e. over-talkativeness, was shared 
by both subscales and could then be included in either 
context. Items no. 8 (racing or crowded thoughts), no. 9 
(subjective or objective irritability), no. 10 (dramatic 
description of suffering or frequent spells of weeping), 
and no. 11 (early or middle insomnia) were further sub-
divided into two sub-items (a and b). Checking “Yes” to 
either (a or b) was considered a positive score. As there 
might be an overlap between depressive anxiety and inner 
tension,21 we wanted to better clarify item no. 7, which 
represented inner tension. We further subdivided it into 
three sub-items (a, b, and c) and for a positive score, a or 
b plus c had to be checked “Yes”. Item no. 13 (represent-
ing signs of retardation) was also subdivided into two sub- 
items (a and b). For a positive score, both sub-items (a and 
b) had to be checked “No”. For the remaining items, 
checking “Yes” to any of them was considered a positive 
score (Appendix).
The original English version was administered to 
a convenience group of English-speaking British patients 
with mood disorders to assess feasibility and face validity. 
The items were then revised on the basis of this experience 
and a final version was approved by the authors. The 
English version was translated into Arabic. Back transla-
tion was performed by a bilingual psychiatrist unaware of 
the original SMDS. A preliminary translated version was 
administered to 50 Arabic patients with mood disorders. 
The Arabic authors of the present study reviewed the 
results of this preliminary investigation, and a final version 
was approved by them. It was considered equivalent to the 
original English version.
The Gold Standard
As it was the first scale of its kind and there was no gold 
standard with which to correlate, SMDS was validated 
against expert interviews as a gold reference standard. 
These interviews were carried out by senior psychiatrists 
with a minimum of 20 years of experience. They were 
blind to SMDS results. The experts used a semi-structured 
interview based on the SCID for DSM-5 (SCID-5) for 
symptoms such as over-talkativeness and racing thoughts.
For symptoms not found in the SCID-5, supplementary 
definitions were given: For psychomotor agitation, some 
questions were taken from Koukopoulos Mixed 
Depression Rating Scale KMDRS:29 “Have you been so 
fidgety and restless that you couldn’t sit still? Do you have 
to keep pacing up and down?”, and we added others, 
following the RDC definition: “Have you kept wringing 
your hands, pulling or rubbing on your hair, skin or clothes? 
Have you had outbursts of complaining or shouting?”
For inner agitation (tension), patients had to score 3 on 
KMDRS item no. 9.29
For crowded thoughts, we followed Koukopoulos’ 
definition, i.e. the patient complains of the stream rather 
than the content: “Have you felt your head full of thoughts 
that you were unable to stop?”
Crowded thoughts should be differentiated from 
depressive ruminations which are few, and the patient 
suffers from the thought content rather than the stream.
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For subjective feelings of unprovoked rage, the patient 
had to score 2 or 3 on KMDRS item no. 6.29
For objective expression of irritability, we followed 
KMDRS corresponding instruction no. 7: Rate overt 
expressions of irritability, annoyance and anger, including 
being argumentative, shouting, losing temper, as well as 
throwing things and being assaultive.
For dramatic description of suffering or frequent spells 
of weeping, patients had to score 2 or 3 on KMDRS.
For initial insomnia, the required score was at least 1 
on the corresponding KMDRS item no. 11, and we fol-
lowed the KMDRS instruction no. 11 in defining middle 
insomnia: Only waking up with agitation and/or difficulty 
falling back to sleep should be rated.
For mood lability, patients should score 3 on the cor-
responding KMDRS item no. 4.
For the definition of retardation, we followed the 
instructions of The Cornell Scale for Depression in 
Dementia CSDD:30 Retardation is characterized by slow 
speech, delayed response to questions and decreased motor 
activity and/or reactions, and we made a small change to 
the question: “Have you been talking or moving more 
slowly than is normal for you?”
Statistical Analysis
Data were collected by expert interviews, previous history 
and scales. Data were then imported into Statistical 
Package for the Social Sciences (SPSS version 20.0) soft-
ware. Qualitative data were represented as number and 
percentage. Quantitative continuous data were represented 
by their means and standard deviations. The following are 
the tests used to assess significant differences:
1. Chi squared tests (X2) to assess difference and asso-
ciation of qualitative variables.
2. t-Tests to assess differences between quantitative 
continuous data. Agreement was tested by Kappa agree-
ment. Significant probability was less than or equal to 0.05 
(P≤0.05). We established a factor analysis to determine the 
extent to which shared variance exists among SMDS vari-
ables within the pool of items.
Results
Socio-Demographic Data
We studied 170 patients with a mean age of 31.04±8.12, 
with minimum 19 and maximum 65; 44.1% were male and 
55.9% were female. A positive family history of bipolar 
disorder was found in 22.9%, as shown in Table 1.
Frequencies and Symptom Endorsements
Regarding RDC-A, the highest symptom endorsement was 
RDC2 (Inability to sit still), the lowest symptom endorse-
ment was RDC6 (Over-talkativeness) and overall RDC-A 
was present in 18.2%, as shown in Figure 1. Regarding 
K-DMX, the highest symptom endorsement was DMX1 
(Absence of signs of retardation), the lowest symptom endor-
sement was DMX2 (Over-talkativeness) and overall K-DMX 
was present in 22.9%, as shown in Figure 2. Regarding 
SMDS items, the highest item endorsement was item no. 
12 (Mood lability) and the lowest was item no. 3 (Hand 
wringing). Pure depression according to SMDS was 61.2% 
and mixed depression was 38.8%, as shown in Table 2.
Internal Consistency
SMDS demonstrated high reliability, and internal consis-
tency was good (Cronbach’s Alpha=0.87).
Factor Analysis
A confirmatory factor analysis identified two components: 
a factor for mixity without psychomotor agitation and 
Table 1 Demographic and Clinical Characteristics of the Sample
Age Mean±SD 31.04±8.12
Median (range) 31.0 (19–65)
Onset Mean±SD 13.28±8.4
Median (range) 17.0 (1–29)
Duration of index 
MDE
Mean±SD 13.62±10.8
Median (range) 4.0 (2–55)
N %
Sex Male 75 44.1
Female 95 55.9
Residence Urban 83 48.8
Rural 87 51.2
Occupation Unemployed 60 35.3
Employed 110 64.7




Education Primary 70 41.2
Preparatory and secondary 88 51.7
High 12 7.1
Family history –VE 131 77.1
+VE 39 22.9
Abbreviations: MDE, major depressive episode; SD, standard deviation; +VE, 
positive; –VE, negative.
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a factor for psychomotor agitation. From item 7 to item 13, 
each item accounted for smaller and smaller amounts of the 
total variance, and items nos. 1, 2, 3, 4, 5, 6 and 13 were 
related to both factors but more to agitation. Items nos. 8 and 
12 were related only to mixity, and items nos. 7, 9, 10 and 11 












RDC1 RDC2 RDC3 RDC4 RDC5 RDC6 All RDC-A.
RDC-A 
Figure 1 RDC-A distribution among studied group. 













DMX1 DMX2 DMX3 DMX4 DMX5 DMX6 DMX7 DMX8 All   K-
DMX.
K-DMX
Figure 2 K-DMX distribution among studied group. 
Notes: DMX1: absence of retardation. DMX2: over talkativeness. DMX3: psychic agitation or inner tension. DMX4: dramatic description of suffering or frequent spells of 
weeping. DMX5: racing/crowded thoughts. DMX6: irritability or unprovoked rage. DMX7: mood lability and marked reactivity. DMX8: early or middle insomnia.
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Association Between Mixity and 
Demographic Characteristics
There were significantly more mixed cases in later age: 
mixed group 35.66±10.25 and pure depression group 
28.11±4.42. The mixed group was further significantly 
associated with being single and with primary and high 
education levels. It was also significantly associated with 
a positive family history of bipolar disorder and moderate 
CGI. However, there was no significant association with 
sex, residence or occupation, as shown in Table 3.
Validity of SMDS
We found significant association and agreement between 
mixity according to SMDS and the gold standard (K-DMX 
according to expert interview) with sensitivity 87.1%, 
specificity 99.2%, +VE predictive 97.1%, –VE predictive 
96.2% and accuracy 96.4%. Also, we found significant 
association and agreement between agitation according to 
SMDS and the gold standard (RDC-A according to expert 
interview) with sensitivity 96.8%, specificity 99.3%, +VE 
predictive 96.7%, –VE predictive 99.2% and accuracy 
98.8%. Regarding overall mixity, we found significant 
association and agreement between overall mixity accord-
ing to SMDS and the gold standard with sensitivity 91.4%, 
specificity 98.0%, +VE predictive 96.9%, –VE predictive 
94.2% and accuracy 95.2% as shown in Table 4.
Discussion
This is the second study assessing, in an outpatient sample, 
the validity of SMDS, a self-rated screening instrument 
designed to measure the non-DSM mixed features in 
depression, as proposed by Koukopoulos. Against an 
expert interview diagnosis of the clinically valid 
Koukopoulos criteria K-DMX, and of the clinically uti-
lized research diagnostic criteria of agitated depression 
RDC-A, which is used as the “gold standard”, the sensi-
tivity against RDC-A was 96.8% and the specificity was 
99.3%; the sensitivity against K-DMX was 87.1% and the 
specificity was 99.2%. Factor analysis identified two com-
ponents that capture the proposed mixed features: a factor 
for psychomotor agitation and a factor for mixity without 
psychomotor agitation. In our study, we found that SMDS 
had good reliability and internal consistency (Cronbach’s 
Alpha=0.87). We also found that mixed states were sig-
nificantly more frequent in later age. This finding is in line 
with some studies31 but contradicts others.4,32–35
Our aim in this, as in our earlier investigation36 was to 
include only patients with unipolar depression. This may 
account for the higher age finding. It is essential to note 
that in patients with non-DSM mixed features, bipolar 
latency is not the only important consideration. The more 
practical and clinically relevant negative impact of anti-
depressant treatment, irrespective of any actual switch to 
frank hypo/mania, must also be borne in mind. Of note, as 
reported,32,34,35,37–39 there was more positive family his-
tory of bipolar disorder in cases with mixed depression.
This is the first self-rated scale of its kind that addresses 
the most common non-DSM mixed features as proposed by 
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Koukopoulos. The Koukopoulos Mixed Depression Rating 
Scale (KMDRS)29 is a clinician-rated scale that captures the 
same construct. However, for a busy clinician, it might be 
time consuming to use it on a regular basis. Another clin-
ician-rated bivariate scale for both manic and depressive 
mixed features has been developed by Cavanagh et al.40 
Table 3 Basic Demographic and Clinical Data Distribution Among Pure Depression and Mixed Groups
Group X2 P
Pure Depression Mixed
Age Mean±SD 28.11±4.42 35.66±10.25 −6.612 0.00**
Sex Male N 52 23 3.76 0.053
% 50.0 34.8
Female N 52 43
% 50.0 65.2
Residence Rural N 46 37 2.26 0.13
% 44.2 56.1
Urban N 58 29
% 55.8 43.9
Occupation Employed N 41 19 2.69 0.18
% 39.4 28.8
Unemployed N 63 47
% 60.6 71.2
Marital status Single N 20 23 15.55 0.001**
% 19.2 34.8
Married N 32 6
% 30.8 9.1
Divorced N 43 35
% 41.3 53.0
Widow N 9 2
% 8.7 3.0
Education Primary N 20 50 88.41 0.00**
% 19.2 75.8
Preparatory and secondary N 84 4
% 80.8 6.1
High N 0 12
% 0.0 18.2
Family history of bipolar disorder No N 94 37 26.9 0.00**
% 90.4 56.1
Yes N 10 29
% 9.6 43.9
CGI Mild N 54 15 14.27 0.00**
% 51.9 22.7
Moderate N 50 51
% 48.1 77.3
Total N 104 66
% 100.0 100.0
Note: **Highly significant.
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However, it limits itself to the DSM-defined manic symp-
toms and neglects the most common excitatory symptoms. 
One other self-rated scale has been developed for mixed 
depression, the CUDOS-M.41 It differs from our scale in 
that it assesses only the DSM-5 mixed specifier. Again, it 
neglects the most common agitation and other excitatory 
symptoms. Defining the basic nature of “psychic depressive 
states”, Griesinger42 stated that the basic nature that under-
lies the psychic depressive states is not inactivity and sup-
pression of the psychic processes. He assumed that the cause 
of such states is mostly an intense state of irritation of the 
brain and excitation of the psychic processes. Following 
Table 4 Association, Agreement and Validity of SMDS
K-DMX According to Expert 
Interview
χ2 P Kappa Agreement
–VE +VE
Mixity according to SMDS –VE N 130 5 124.5 0.00** 0.82
% 99.2 12.9
+VE N 1 34
% 0.8 87.1
Total N 131 39
Validity Sensitivity Specificity +VE Predictive –VE Predictive Accuracy
87.1% 99.2% 97.1% 96.2% 96.4%
RDC-A According to Expert 
Interview
X2 P Kappa Agreement
–VE +VE
Agitation according to SMDS –VE N 138 1 156.85 0.00** 0.95
% 99.3 3.2
+VE N 1 30
% 0.7 96.8
Total N 139 31
Validity Sensitivity Specificity +VE Predictive –VE Predictive Accuracy
96.8% 99.3% 96.7% 99.2% 98.9%
Overall Mixity According to Expert 
Interview
χ2 P Kappa Agreement
–VE +VE
Overall mixity by SMDS –VE N 98 6 146.1 0.00** 0.91
% 98.0 8.6
+VE N 2 64
% 2.0 91.4
Total N 100 70
Validity Sensitivity Specificity +VE Predictive –VE Predictive Accuracy
91.4% 98.0% 96.9% 94.2% 95.2%
Note: **Highly significant.
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Griesinger’s use of the phrase “excitation of the psychic 
processes”, and given what is really encountered in clinical 
practice, we suggest, just like others,24 that mixed symptoms 
of depression might be better called excitatory rather than 
hypo/manic symptoms. Patients with excitatory (mixed) 
depression lack expansiveness and easy performance of 
activities. They are tormented by their psychic pain and 
unable to perform activities.24 However, we are not inclined 
to abandon the DSM-5-defined mixed specifier or assume it 
is nothing but a kind of mixed hypomania as proposed 
elsewhere.24 Also, one cannot claim, as it is the case in 
expansive mixity, that excitatory mixity could be a marker 
of bipolarity. Instead, the negative impact of antidepressants 
on such symptoms, be they excitatory or expansive, is what 
we insist on and develop the scale to guard against. The 
same might be argued for psychomotor agitation which is 
represented in the first subscale. The utility of the concept of 
psychomotor agitation as a mixed feature is supported by the 
negative impact of antidepressants on it and by being 
a precursor to suicidality related or unrelated to 
antidepressants.35,43–46 Based on the notion that 
a definition of mixed depression which will better show 
the impact of treatment is the definition of choice in clinical 
practice,44 K-DMX and RDC-A should be considered 
important and clinically relevant mixed features in depres-
sion and the development of a scale as an aid to capture them 
is worthwhile.
Limitations
1. The assessment was cross-sectional; thus, we did 
not examine the long-term stability of the scale.
2. As the study was conducted in a sample of out-
patients, replication in other samples with different 
clinical characteristics might be warranted.
3. Taking in consideration the patients’ extreme suf-
fering as well as the reported dramatic, unique and 
fast improvement on Olanzapine alone in such 
mixed cases,22,36,47 we did not delay the use of 
Olanzapine at the expense of assessing test-retest 
reliability.
Conclusion
The SMDS showed good psychometric properties with good 
internal consistency, high sensitivity, specificity, positive 
predictive value and negative predictive value. It demon-
strated a two-factor structure; one for mixity without psy-
chomotor agitation and another for psychomotor agitation.
Overall, SMDS can be considered a useful instrument 
for measuring the non-DSM mixed features in UP as 
proposed by Koukopoulos. We recommend the routine 
use of our scale in all apparently depressed patients in 
order to screen for a possible clinically relevant mixity. 
In addition, we recommend conducting further studies on 
what Koukopoulos named excitatory symptoms. We 
hypothesize that such excitatory symptoms could consti-
tute a third polarity or, at the very least, fall on 
a continuum between inhibited/retarded depression and 
expansive hypo/mania.
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